SacredBod's longer take on Strontium Citrate — context the structured blocks above don't capture.
Strontium citrate exists in a peculiar regulatory and evidence gap. The prescription form — strontium ranelate (Protelos, Osseor) — has robust clinical trial evidence showing 41% reduction in vertebral fractures and 16% reduction in non-vertebral fractures over 5 years in postmenopausal women with osteoporosis. But it was withdrawn from the European market and restricted elsewhere because it increases the risk of venous thromboembolism and serious cardiovascular events. Strontium citrate, the over-the-counter supplement form, contains the same active element (strontium) but has zero large-scale RCT evidence for efficacy or safety. Supplement marketers exploit this gap, implying the fracture benefits of ranelate while selling an unproven salt with unknown cardiovascular risk.
The mechanism is genuinely interesting. Strontium is chemically similar to calcium and incorporates into bone hydroxyapatite crystals. Unlike calcium, which primarily supports bone mineralization, strontium has dual activity: it stimulates osteoblasts (bone-building cells) to produce more bone matrix, while simultaneously inhibiting osteoclasts (bone-resorbing cells) through downregulation of RANKL signaling. This dual action produces rapid increases in bone mineral density — often 5–10% within 1–2 years — that exceed what bisphosphonates achieve. But BMD increases with strontium are partly artifactual because strontium atoms are heavier than calcium atoms and exaggerate DEXA readings.
Reginster’s 2014 analysis in Bone summarized the ranelate fracture data from the SOTI and TROPOS trials: 41% reduction in vertebral fractures and 16% reduction in non-vertebral fractures over 5 years. These are real, clinically meaningful benefits. But the same trials and subsequent post-marketing surveillance revealed the safety problem: increased risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism), myocardial infarction, and stroke. In 2013, the European Medicines Agency restricted strontium ranelate to patients with severe osteoporosis who could not use other treatments and had no cardiovascular risk factors. In 2017, it was withdrawn entirely in the EU.
The critical question for strontium citrate is whether the cardiovascular risks are specific to the ranelate salt or inherent to strontium itself. No one knows. The ranelate anion is not biologically active — it is a carrier molecule that delivers strontium to bone. The cardiovascular effects are likely attributable to strontium’s systemic effects on vascular calcification, clotting factors, or calcium channel modulation. If this is true, strontium citrate would carry the same risks without the same benefits, because no fracture trial has ever tested it.
The honest framing is that strontium citrate is a gamble. It may provide some bone density benefit — the pharmacokinetic data show that citrate delivers bioavailable strontium to bone — but the magnitude of benefit is unknown, and the safety profile is uncharacterized. For someone with severe osteoporosis who cannot tolerate bisphosphonates or denosumab, it may be a reasonable option under close medical supervision with cardiovascular monitoring. For the general population seeking “bone health,” the risk-benefit ratio is unfavorable compared to calcium, vitamin D, vitamin K2, magnesium, and weight-bearing exercise.
Practical guidance: If you and your physician decide to try strontium citrate, the typical dose is 300–680 mg elemental strontium daily, taken at bedtime on an empty stomach, separated from calcium by at least 2 hours. Monitor bone density every 1–2 years. If you have any history of cardiovascular disease, heart attack, stroke, blood clots, or uncontrolled hypertension, do not use strontium in any form. Do not substitute strontium citrate for proven osteoporosis medications without medical supervision. In India, strontium citrate is available from HealthyHey and some specialty supplement brands.
